miR-30a-5p has been found regulating tumor development by inhibiting oncogenes in various tumors [19, 22, 23], and it can enhance the sensitivity of NSCLC to paclitaxel by targeting BCL-2 expression [24]. This evidence concerns the gene BCL2 and non-small cell lung carcinoma.